GlassScriptPhysician profile
Queen Tochi Ajiere
NPI 1730890898
$5,300.09
in general payments reported to CMS, 2019-2025
25 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $2,381 · 2024: $1,275 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,105.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,217.18 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $492.51 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $477.63 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $425.80 | 2022-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $419.33 | 2023-2025 | Austedo, Austedo Xr, Uzedy |
| Alkermes, INC. | $383.97 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $257.21 | 2023-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $206.80 | 2022-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $204.12 | 2023-2024 | Quviviq |
| Tris Pharma INC | $197.71 | 2023-2025 | Dyanavel Xr |
| Lundbeck LLC | $125.01 | 2023-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $112.83 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $94.47 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $90.42 | 2023-2024 | Auvelity |
| Neuronetics, INC. | $88.77 | 2022-2023 | Neurostar Tms Therapy System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $87.45 | 2023-2024 | Trintellix |
| Indivior INC. | $85.65 | 2023-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $75.81 | 2024-2025 | Qelbree, Xyosted, Tlando |
| Vanda Pharmaceuticals INC. | $58.25 | 2025 | Fanapt |
| Braeburn INC. | $57.81 | 2025 | Brixadi |
| Novo Nordisk INC | $44.05 | 2024-2025 | Wegovy |
| Ironshore Pharmaceuticals INC. | $33.75 | 2023-2024 | Jornay Pm |
| Harmony Biosciences LLC | $26.90 | 2024 | |
| Halozyme INC | $19.53 | 2023 | |
| Lilly USA, LLC | $17.13 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Queen Ajiere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.